Evaluation of Statin Indication and Dose Intensification Among Type 2 Diabetic Patients at a Tertiary Hospital
Pineal Fisseha,Assefa Baye,Melak Beyene,Eyasu Makonnen
DOI: https://doi.org/10.2147/dmso.s446711
2024-03-07
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Pineal Yitbarek Fisseha, 1 Assefa Mulu Baye, 2 Melak Gedamu Beyene, 2 Eyasu Makonnen 2 1 Tikur Anbessa Specialized Hospital, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2 Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Correspondence: Assefa Mulu Baye, Addis Ababa University, Addis Ababa, Ethiopia, Tel +251910980410, Email Background: Diabetes mellitus (DM) increases cardiovascular disease (CVD) incidence and mortality. While guidelines endorse statin use in type 2 DM (T2DM) to mitigate cardiovascular risks and mortality, challenges like statin initiation and prompt treatment adjustments affect patient outcomes. This study aimed to assess the appropriateness of indications for and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). Methodology: A hospital-based cross-sectional study was conducted from April 1 to June 30 2020. In total, 405 T2DM patients were selected using a systematic random sampling technique. The data were analyzed using SPSS version 26.0. An adjusted odds ratio (OR) was used and a 95% confidence interval (CI) and p-values of < 0.05 were utilized to determine statistical significance. Results: Of the total 405 participants, 346 (85.4%) started taking statins for primary or secondary prevention purposes. Indication for statin use was appropriate in 96.2% patients, while for 216 (62.4%) patients their doses were appropriately intensified. Predictors of the inappropriateness of statin use were an atherosclerotic cardiovascular disease (ASCVD) score of ≥ 7.5% (AOR=0.28; 95% CI: 0.102– 0.738, p=0.01), the presence of dyslipidemia (AOR=4.48; 95% CI: 1.85– 10.84; p=0.001), initiation of aspirin therapy (AOR=3.7; 95% CI: 1.522– 9.144; p=0.004), and an LDL-cholesterol level of 70– 189 mg/dL (AOR=0.124; 95% CI: 0.042– 0.365; p=0.001). DM duration of ≥ 10 years (AOR=2.51; 95% CI: 1.35– 4.66, p=0.004), male gender (AOR=2.04; 95% CI: 1.16– 3.58, p=0.013), age ≥ 65 years (AOR=2.15; 95% CI: 1.23– 3.75, p=0.007) and uncontrolled blood pressure (AOR=2.09; 95% CI: 1.07– 4.08, p=0.031) were associated with inappropriate statin intensification. Conclusion: The study found that indication of statins was optimal and about two-thirds of patients had their doses appropriately intensified. Monitoring is needed to avoid inappropriate intensification of statin therapy, particularly in patients with longer diabetes duration, those of male gender and advanced age, and those with uncontrolled blood pressure. Keywords: atherosclerotic cardiovascular disease, diabetes mellitus, statin therapy Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by hyperglycemia due to insulin resistance resulting in vascular complications. It accounts for approximately 75% of all atherosclerosis-related events. 1 Moreover, 65% of patients with diabetes die from any type of cardiovascular disease or stroke. Currently, lipid-lowering statin therapy is recommended for the primary prevention of atherosclerotic cardiovascular diseases, as well as for secondary prevention in DM patients with established cardiovascular disease. 2,3 The cardiovascular effects of statins extend beyond their effects on lipid fractions and include atherosclerotic plaque stabilization, anti-inflammatory effects, inhibition of vascular smooth muscle cell proliferation, inhibition of platelet function, and improved vascular endothelial function. 4 Since the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) blood cholesterol guidelines, there has been a shift from treating with a fixed LDL-C target to selecting appropriate intensity statin therapy based on individual atherosclerotic cardiovascular disease (ASCVD) risk. 5 Despite current guidelines in routine clinical practice, statin intolerance and other factors may lead to treatment discontinuation, switching among statin agents, dose adjustments, or the need for augmentation of the statin regimen impacting therapeutic benefits and patient outcomes. 6 The implementation of these guidelines is often poor and statin prescribing for patients with diabetes has been shown in some studies to be sub-optimal. 7,8 A study in the Netherlands indicated that around 22% of T2DM patients were started on statin treatment at a dose lower than recommended and more than half of them remained on a low dose during a 2-year follow-up period; less than 15% received an increased dose. 9 Another study, in the United Kingdom, showed that 43% of patients with atherosclerotic CVD discontinued thei -Abstract Truncated-
endocrinology & metabolism